Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas

Plain-language summary

This is an observational study that comprehensively examines the outcomes of chemotherapy and targeted therapies (Bevacizumab-containing or non-Bevacizumab regimens and BRAF ± MEK targeted therapy) in patients with recurrent malignant glioma, a type of brain tumor. It focuses on patients aged 18 and older with a molecularly confirmed malignant glioma diagnosis per the WHO 2021 classification whose disease has recurred or progressed. It is a study with no assigned phase and is active but not currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Blokhin's Russian Cancer Research Center

Intervention

Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy

Start date

2/1/2026

Estimated completion

10/1/2027

Countries

Russia

Related genes

Locations

• Moscow, Russia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥ 18 years at the time of initial brain tumor diagnosis;
* Histologically confirmed diagnosis of malignant glioma, including:

  * Glioblastoma, IDH-wildtype (WHO grade 4)
  * Astrocytoma, IDH-mutant (WHO grade 3-4)
  * Pleomorphic xanthoastrocytoma (WHO grade 2-3)
* Molecularly confirmed diagnosis according to WHO 2021 classification (with available data on IDH1/2, BRAF, 1p/19q, and MGMT status where applicable);
* Documented disease recurrence or progression with available treatment-related data in medical records to assess at least one of the study outcome measures

Exclusion Criteria:

* Age \< 18 years at initial diagnosis;
* Absence of molecular-genetic confirmation of the tumor (according to WHO 2021 classification);
* Lack of documented disease recurrence or progression, or insufficient treatment-related data in medical records to assess at least one of the study outcome measures;
* Prior participation in clinical trials with unblinded investigational agents where data cannot be extracted (except where data are available and verifiable);
* Synchronous primary malignant neoplasms.